BPC-157 vs PE-22-28
Extensively Studied vs Emerging
compatible Different mechanisms, no contraindications.
Molecular Data
BPC-157 PE-22-28
Weight 1,419.53 Da 773.89 Da
Half-life <30 minutes Approximately 23 hours
Chain 15 amino acids 7 amino acids
Type Pentadecapeptide Linear heptapeptide
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
PE-22-28
01 Rapid antidepressant effects within 4 days (preclinical)
02 Hippocampal neurogenesis and synaptogenesis
03 Enhanced serotonergic neurotransmission
04 Extended ~23 hour duration of action
05 300-500x greater potency than full-length Spadin
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
PE-22-28
50-200mcg daily / Once daily
Antidepressant Effect 50-200mcg Once daily
Neurogenesis Support 100-200mcg Once daily
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
PE-22-28
No effects on TREK-2, TRAAK, TASK-1 channels observed
No cardiac dysfunction or seizures in preclinical studies
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Pregnancy and breastfeeding
Concurrent MAOI use
Research Evidence
BPC-157 PE-22-28
Status Extensively Studied Emerging
References 6 studies 3 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.